BioCentury
ARTICLE | Clinical News

Daratumumab regulatory update

October 5, 2015 7:00 AM UTC

EMA accepted and granted accelerated assessment to an MAA from Johnson & Johnson for daratumumab to treat multiple myeloma (MM) in patients who have received >=3 prior lines of therapy, including both...